Ampio Pharma (AMPE) Announces Additional Publication of Ampion Modes of Action

August 30, 2016 8:05 AM EDT
Get Alerts AMPE Hot Sheet
Trade AMPE Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Ampio Pharmaceuticals, Inc. (NYSE: AMPE) announced publication in the peer-reviewed journal Biochemistry and Biophysics Reports that further describes the modes of action (MOA) of Ampion in the treatment of Osteoarthritis. The publication is titled:

"The low molecular weight fraction of human serum albumin upregulates COX2, prostaglandin E2, and prostaglandin D2 under inflammatory conditions in osteoarthritic knee synovial fibroblasts." Elizabeth D. Frederick, Ph.D.; Melissa A. Hausburg, Ph.D.; Gregory W. Thomas, BS; Leonard Rael, MS; Edward Brody, MD; David Bar-Or, MD and can be retrieved at

Dr. David Bar-Or, Ampio's Chief Science Officer, noted, "This manuscript reports that in the presence of either IL-1β or TNFα, LMWF-5A (Ampion™) increased the expression of both COX2 mRNA and protein, and this increase was significant compared to that observed with IL-1β- or TNFα-stimulated, saline-treated cells. LMWF-5A appears to trigger increased anti-inflammatory PG signaling, and this may be a primary component of its therapeutic mode of action in the treatment of OAK." In simple words, these findings indicate that the mechanism of action of Ampion™ is through the production of beneficial prostaglandins by synoviocytes for both the resolution of inflammation and tissue regeneration.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Management Comments

Add Your Comment